Search research articles
Contact Us
Filters
Showing results (1-10 of 94) with videos related to
Page
of 10
Sort By:
Postgraduate Medicine
|
June 20, 2020
Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin
Craig J Currie
Respiratory Medicine
|
September 15, 2007
CHKS data should be avoided when investigating mortality
Craig J Currie
The New England Journal of Medicine
|
November 2, 2012
Basal insulin and cardiovascular and other outcomes
Guntram Schernthaner, Craig J Currie
Current Medical Research and Opinion
|
November 27, 2008
Descriptive epidemiology of hospitalisation for psoriasis
Pete Conway, Craig J Currie
Heart (British Cardiac Society)
|
March 19, 2014
Lipid-lowering therapy and mortality post-MI: is it just about the LDL?
Julian P Halcox, Craig J Currie
Pharmacoeconomics
|
September 1, 2006
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes
Andrew J Palmer, Craig J Currie
Human Reproduction (Oxford, England)
|
July 5, 2006
Randomized single versus double embryo transfer studies: obstetric and paediatric outcome and a cost-effectiveness analysis
Craig J Currie, Jaroslaw G Wechowski
Atherosclerosis
|
March 6, 2012
Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities
Sarah E Holden, Craig J Currie
BMJ (Clinical Research Ed.)
|
October 13, 2007
Let cost effectiveness models be open to scrutiny
Chris Poole, Samir Agrawal, Craig J Currie
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository
Simon Dixon, Craig J Currie, Phil McEwan
Page
of 10
Search research articles
Search
Showing results (1-10 of 94) with videos related to
Sort By:
Page
of 10
Postgraduate Medicine
|
June 20, 2020
Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin
Craig J Currie
Respiratory Medicine
|
September 15, 2007
CHKS data should be avoided when investigating mortality
Craig J Currie
The New England Journal of Medicine
|
November 2, 2012
Basal insulin and cardiovascular and other outcomes
Guntram Schernthaner, Craig J Currie
Current Medical Research and Opinion
|
November 27, 2008
Descriptive epidemiology of hospitalisation for psoriasis
Pete Conway, Craig J Currie
Heart (British Cardiac Society)
|
March 19, 2014
Lipid-lowering therapy and mortality post-MI: is it just about the LDL?
Julian P Halcox, Craig J Currie
Pharmacoeconomics
|
September 1, 2006
Modelling lifetime metabolic progression and cost effectiveness of treatment strategies for type 2 diabetes
Andrew J Palmer, Craig J Currie
Human Reproduction (Oxford, England)
|
July 5, 2006
Randomized single versus double embryo transfer studies: obstetric and paediatric outcome and a cost-effectiveness analysis
Craig J Currie, Jaroslaw G Wechowski
Atherosclerosis
|
March 6, 2012
Endogenous hyperinsulinaemia and exogenous insulin: a common theme between atherosclerosis, increased cancer risk and other morbidities
Sarah E Holden, Craig J Currie
BMJ (Clinical Research Ed.)
|
October 13, 2007
Let cost effectiveness models be open to scrutiny
Chris Poole, Samir Agrawal, Craig J Currie
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 8, 2009
Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository
Simon Dixon, Craig J Currie, Phil McEwan
Page
of 10